News
SGHT
8.14
+1.69%
0.14
Weekly Report: what happened at SGHT last week (0831-0904)?
Weekly Report · 4d ago
Weekly Report: what happened at SGHT last week (0824-0828)?
Weekly Report · 08/31 10:31
Weekly Report: what happened at SGHT last week (0817-0821)?
Weekly Report · 08/24 10:31
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Moderna (MRNA), Merck & Company (MRK) and Sight Sciences (SGHT)
TipRanks · 08/19 13:30
Sight Sciences' TearCare Becomes First FDA-Approved MGD Therapy For Dry Eye Disease; Stock Up
NASDAQ · 08/19 12:29
Sight Sciences Announces FDA Label Expansion For TearCare Dry Eye Therapy
NASDAQ · 08/19 11:50
Sight Sciences announces updated TearCare System Indications for Use
TipRanks · 08/19 11:35
Sight Sciences Announces Updated FDA Indications For TearCare, Effective August 18
Benzinga · 08/19 11:10
TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease
Barchart · 08/19 06:05
Sight Sciences Earnings Call Shows Growth And Discipline
TipRanks · 08/18 00:20
Weekly Report: what happened at SGHT last week (0810-0814)?
Weekly Report · 08/17 10:32
Citi Remains a Hold on Sight Sciences (SGHT)
TipRanks · 08/13 16:15
Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript
The Motley Fool · 08/12 23:29
Sight Sciences Appoints New Chief Legal Officer Rashid
TipRanks · 08/10 12:59
Weekly Report: what happened at SGHT last week (0803-0807)?
Weekly Report · 08/10 10:27
Top Biotech Gainers: CELZ Soars On Patent News, BRVE Debuts Strong, IOVA Revenue Climbs 66%
NASDAQ · 08/07 02:30
Sight Sciences Is Maintained at Buy by UBS
Dow Jones · 08/06 19:50
UBS Maintains Buy on Sight Sciences, Raises Price Target to $8
Benzinga · 08/06 19:40
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sight Sciences (SGHT)
TipRanks · 08/06 18:50
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 08/06 17:06
More
Webull provides a variety of real-time SGHT stock news. You can receive the latest news about Sight Sciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SGHT
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.